search
Back to results

A Novel Technique Of Uterine Cooling During Repeated Cesarean Section For Reducing Blood Loss

Primary Purpose

Cesarean Section Complications, Intrapartum Hemorrhage, Postpartum Hemorrhage

Status
Completed
Phase
Not Applicable
Locations
Egypt
Study Type
Interventional
Intervention
Uterine Cooling Technique
Sponsored by
Al-Azhar University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Cesarean Section Complications

Eligibility Criteria

20 Years - 40 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Singleton pregnancy at term between 38±5 days and 40 weeks.
  • Elective planned or emergency repeated lower segment cesarean sections(LSCS).
  • Pregnant women who will accept to be in the study, and have giveninformed consent.

Exclusion Criteria:

Women who refuse to be in the study, and women who are unable to consentdue to emergent nature of the cesarean section will be excluded. Women whoare unable to understand the nature of the study due to mental illness, mentalretardation, medical condition, or other communication barrier will be excluded,or who with severe medical and surgical complications as any of the followingwill be excluded :

  • Heart, liver, kidney, or brain diseases, and blood disorders.
  • Abruptio placenta, and placental abnormalities or accrete syndromes.
  • Polyhydraminos, macrosomia, or preeclampsia.
  • History of thromboembolic disorders, or severe anemia.

Sites / Locations

  • OB/GYN Departments, Al-Hussein University Hospital, Al-Azhar University

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Active Comparator

Arm Label

Control

Study

Arm Description

Standard Lower Segment Cesarean Section (LSCS) will be done.

Uterine Cooling Technique: Standard LSCS will be done except immediately following delivery of the fetus the uterus will be externalized in the usual fashion and the body of the uterus cephalad to the hysterotomy incision will be wrapped in sterile surgical towels saturated in sterile, iced normal saline. These towels will come from a sterile cooling pot set to 30 degrees Fahrenheit. The skin of the abdomen will be draped to prevent contact with the cold towels. Iced saline-soaked towels will be kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen.

Outcomes

Primary Outcome Measures

Intra-operative Blood Loss (ml)
Estimating Blood Loss during LSCS immediately after delivery of the fetus and prior to delivery of the placenta till closure of uterine incision.
Post-operative Vaginal Blood Loss (ml)
Estimating Vaginal Blood Loss (ml) during 6 hours post LSCS.

Secondary Outcome Measures

Change in Pre- versus Post-operative Hemoglobin value.
Recording change in Pre- versus Post-operative Hemoglobin (g/dl) value.
Change in Pre- versus Post-operative Hematocrit value.
Recording change in Pre- versus Post-operative Hematocrit (%) value.
Use of extra Oxytocin (more than 5 i.u.).
Use of extra Oxytocin (more than 5 i.u.).
Use of Methergine.
Use of Methergine.
Use of Misopristole.
Use of Misopristole.
Requirement of blood products.
Requirement of blood products during Intra- and 6 hours Post-LSCS.
Total blood loss greater than 1000 cc.
Total blood loss (ml) greater than 1000 cc.
Use of any additional measures to control blood Loss, including any pharmacological or surgical interventions.
Use of any additional measures to control blood Loss, including any pharmacological or surgical interventions.
Total time uterus wrapped during hysterotomy repair.
Total time (minutes) uterus wrapped during hysterotomy repair.
Uterine temperature after wrap removal.
Uterine temperature (Fahrenheit) after wrap removal recorded by infrared thermometer.
Patient temperature pre, intra, and postoperative.
Patient temperature (Fahrenheit) pre, intra, and during first 6 hours postoperative.

Full Information

First Posted
December 31, 2018
Last Updated
April 8, 2019
Sponsor
Al-Azhar University
search

1. Study Identification

Unique Protocol Identification Number
NCT03793153
Brief Title
A Novel Technique Of Uterine Cooling During Repeated Cesarean Section For Reducing Blood Loss
Official Title
A Novel Technique Of Uterine Cooling During Repeated Cesarean Section For Reducing Blood Loss
Study Type
Interventional

2. Study Status

Record Verification Date
April 2019
Overall Recruitment Status
Completed
Study Start Date
December 19, 2018 (Actual)
Primary Completion Date
March 20, 2019 (Actual)
Study Completion Date
March 25, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Al-Azhar University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Study aim to evaluate the efficacy and safety of a novel technique of UTERINE COOLING during repeated cesarean section (CS) in reducing blood loss, and record any adverse effects following it.
Detailed Description
Bleeding during vaginal or operative delivery is always of prime concern. Despite significant progress in obstetric care 125,000 women die from obstetric hemorrhage annually in the world. The incidence of caesarean delivery is increasing, and the average blood loss during caesarean delivery (1000 mL) is double the amount lost during vaginal delivery (500 mL). Caesarean section (CS) rate as high as 25-30% in many areas of the world. In Egypt the CS rate is 27.6 %, in United States of America, from 1970-2009 the CS rate rose from 4.5-32.9%, and declined to 32.8% of all deliveries at 2010. In spite of the various measures to prevent blood loss during and after caesarean section, post-partum hemorrhage (PPH) continues to be the most common complication seen in almost 20% of the cases, and causes approximately 25% of maternal deaths worldwide, leading to increased maternal morbidity and mortality. Indeed we need to reduce the bleeding during and after caesarean sections aiming for reducing the morbidity and mortality rate due to obstetric hemorrhage, which can be life threatening. The hematocrit level falls by 10% and blood transfusion is required in 6% of women undergoing caesarean delivery versus 4% of women who have a vaginal birth. Numerous methods for performing caesarean section exist targeting a safe delivery for the infant with minimum maternal morbidity. Operative morbidity includes hemorrhage, anemia, and blood products transfusion may be required associated with many risks and complications. Women who undergo a caesarean delivery are much more likely to be delivered by a repeat operation in subsequent pregnancies. For women undergoing subsequent cesarean, the maternal risks are even greater like massive obstetric hemorrhage, hysterectomy, admission to an intensive care unit, or maternal death. Medications, such as oxytocin, misoprostol and prostaglandin F2α, have been used to control bleeding postoperatively. The uterus is a smooth muscle whose contraction is modulated most directly by intrinsic or extrinsic oxytocin. During pregnancy the spiral arteries within the uterus and beneath the placenta enlarge to provide adequate perfusion to the placenta. After separation of the placenta the uterine smooth muscle cells contract in a pincer-like action to pinch the spiral arteries closed. When uterine contraction is inadequate (approximately 4-6% of normal pregnancies) the spiral arteries continue to bleed. If not addressed the bleeding can be excessive, even leading to maternal death. Approximately 5-8 out of 1,000 cesarean sections require hysterectomy to control bleeding. Release of calcium ions from sarcoplasmic reticulum stores is the immediateinitiator of contraction, and calcium's diffusion from the muscle filaments andre-uptake by the sarcoplasmic reticulum results in relaxation of contraction. Insome smooth muscles cold enhances contraction; perhaps by slowing the re-uptake of calcium.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cesarean Section Complications, Intrapartum Hemorrhage, Postpartum Hemorrhage, Atony, Uterine

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Care ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
99 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Control
Arm Type
No Intervention
Arm Description
Standard Lower Segment Cesarean Section (LSCS) will be done.
Arm Title
Study
Arm Type
Active Comparator
Arm Description
Uterine Cooling Technique: Standard LSCS will be done except immediately following delivery of the fetus the uterus will be externalized in the usual fashion and the body of the uterus cephalad to the hysterotomy incision will be wrapped in sterile surgical towels saturated in sterile, iced normal saline. These towels will come from a sterile cooling pot set to 30 degrees Fahrenheit. The skin of the abdomen will be draped to prevent contact with the cold towels. Iced saline-soaked towels will be kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen.
Intervention Type
Procedure
Intervention Name(s)
Uterine Cooling Technique
Other Intervention Name(s)
Hetta-UCT
Intervention Description
Standard LSCS will be done except immediatelyfollowing delivery of the fetus the uterus will beexternalized in the usual fashion and the body of theuterus cephalad to the hysterotomy incision will bewrapped in sterile surgical towels saturated in sterile,iced normal saline. These towels will come from asterile cooling pot set to 30 degrees Fahrenheit. Theskin of the abdomen will be draped to prevent contactwith the cold towels. Iced saline-soaked towels will bekept in place for a minimum of 5 minutes and replacedat the discretion of the attending obstetrician until thehysterotomy is closed and the uterus is replaced intothe patient's abdomen.
Primary Outcome Measure Information:
Title
Intra-operative Blood Loss (ml)
Description
Estimating Blood Loss during LSCS immediately after delivery of the fetus and prior to delivery of the placenta till closure of uterine incision.
Time Frame
20 minutes
Title
Post-operative Vaginal Blood Loss (ml)
Description
Estimating Vaginal Blood Loss (ml) during 6 hours post LSCS.
Time Frame
6 hours
Secondary Outcome Measure Information:
Title
Change in Pre- versus Post-operative Hemoglobin value.
Description
Recording change in Pre- versus Post-operative Hemoglobin (g/dl) value.
Time Frame
48 hours post operative period
Title
Change in Pre- versus Post-operative Hematocrit value.
Description
Recording change in Pre- versus Post-operative Hematocrit (%) value.
Time Frame
48 hours post operative period
Title
Use of extra Oxytocin (more than 5 i.u.).
Description
Use of extra Oxytocin (more than 5 i.u.).
Time Frame
20 minutes
Title
Use of Methergine.
Description
Use of Methergine.
Time Frame
6 hours
Title
Use of Misopristole.
Description
Use of Misopristole.
Time Frame
6 hours
Title
Requirement of blood products.
Description
Requirement of blood products during Intra- and 6 hours Post-LSCS.
Time Frame
6 hours
Title
Total blood loss greater than 1000 cc.
Description
Total blood loss (ml) greater than 1000 cc.
Time Frame
7 hours
Title
Use of any additional measures to control blood Loss, including any pharmacological or surgical interventions.
Description
Use of any additional measures to control blood Loss, including any pharmacological or surgical interventions.
Time Frame
7 hours
Title
Total time uterus wrapped during hysterotomy repair.
Description
Total time (minutes) uterus wrapped during hysterotomy repair.
Time Frame
30 minutes
Title
Uterine temperature after wrap removal.
Description
Uterine temperature (Fahrenheit) after wrap removal recorded by infrared thermometer.
Time Frame
Less than one minute
Title
Patient temperature pre, intra, and postoperative.
Description
Patient temperature (Fahrenheit) pre, intra, and during first 6 hours postoperative.
Time Frame
7 hours

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Singleton pregnancy at term between 38±5 days and 40 weeks. Elective planned or emergency repeated lower segment cesarean sections(LSCS). Pregnant women who will accept to be in the study, and have giveninformed consent. Exclusion Criteria: Women who refuse to be in the study, and women who are unable to consentdue to emergent nature of the cesarean section will be excluded. Women whoare unable to understand the nature of the study due to mental illness, mentalretardation, medical condition, or other communication barrier will be excluded,or who with severe medical and surgical complications as any of the followingwill be excluded : Heart, liver, kidney, or brain diseases, and blood disorders. Abruptio placenta, and placental abnormalities or accrete syndromes. Polyhydraminos, macrosomia, or preeclampsia. History of thromboembolic disorders, or severe anemia.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Amro M. Hetta, M. Sc.
Organizational Affiliation
OB/GYN Departments, Al-Hussein University Hospital, Al-Azhar University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Abdallah K. Ahmed, MD
Organizational Affiliation
OB/GYN Departments, Al-Hussein University Hospital, Al-Azhar University
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Mofeed F. Mohamed, MD
Organizational Affiliation
OB/GYN Departments, Al-Hussein University Hospital, Al-Azhar University
Official's Role
Study Chair
Facility Information:
Facility Name
OB/GYN Departments, Al-Hussein University Hospital, Al-Azhar University
City
Cairo
Country
Egypt

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
All IPD that underlie results in a publication
IPD Sharing Time Frame
After publishing
IPD Sharing Access Criteria
Full text
Citations:
PubMed Identifier
24348295
Citation
Goswami U, Sarangi S, Gupta S, Babbar S. Comparative evaluation of two doses of tranexamic acid used prophylactically in anemic parturients for lower segment cesarean section: A double-blind randomized case control prospective trial. Saudi J Anaesth. 2013 Oct;7(4):427-31. doi: 10.4103/1658-354X.121077.
Results Reference
background
PubMed Identifier
12709915
Citation
Hellgren M. Hemostasis during normal pregnancy and puerperium. Semin Thromb Hemost. 2003 Apr;29(2):125-30. doi: 10.1055/s-2003-38897.
Results Reference
background
PubMed Identifier
26226243
Citation
Wang HY, Hong SK, Duan Y, Yin HM. Tranexamic acid and blood loss during and after cesarean section: a meta-analysis. J Perinatol. 2015 Oct;35(10):818-25. doi: 10.1038/jp.2015.93. Epub 2015 Jul 30.
Results Reference
background
PubMed Identifier
26341174
Citation
Maged AM, Helal OM, Elsherbini MM, Eid MM, Elkomy RO, Dahab S, Elsissy MH. A randomized placebo-controlled trial of preoperative tranexamic acid among women undergoing elective cesarean delivery. Int J Gynaecol Obstet. 2015 Dec;131(3):265-8. doi: 10.1016/j.ijgo.2015.05.027. Epub 2015 Aug 15.
Results Reference
background
PubMed Identifier
25068947
Citation
Ahmed MR, Sayed Ahmed WA, Madny EH, Arafa AM, Said MM. Efficacy of tranexamic acid in decreasing blood loss in elective caesarean delivery. J Matern Fetal Neonatal Med. 2015 Jun;28(9):1014-8. doi: 10.3109/14767058.2014.941283. Epub 2014 Jul 28.
Results Reference
background
PubMed Identifier
21872857
Citation
Movafegh A, Eslamian L, Dorabadi A. Effect of intravenous tranexamic acid administration on blood loss during and after cesarean delivery. Int J Gynaecol Obstet. 2011 Dec;115(3):224-6. doi: 10.1016/j.ijgo.2011.07.015. Epub 2011 Aug 27.
Results Reference
background
PubMed Identifier
20554319
Citation
CRASH-2 trial collaborators; Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, El-Sayed H, Gogichaishvili T, Gupta S, Herrera J, Hunt B, Iribhogbe P, Izurieta M, Khamis H, Komolafe E, Marrero MA, Mejia-Mantilla J, Miranda J, Morales C, Olaomi O, Olldashi F, Perel P, Peto R, Ramana PV, Ravi RR, Yutthakasemsunt S. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010 Jul 3;376(9734):23-32. doi: 10.1016/S0140-6736(10)60835-5. Epub 2010 Jun 14.
Results Reference
background
PubMed Identifier
16738145
Citation
Silver RM, Landon MB, Rouse DJ, Leveno KJ, Spong CY, Thom EA, Moawad AH, Caritis SN, Harper M, Wapner RJ, Sorokin Y, Miodovnik M, Carpenter M, Peaceman AM, O'Sullivan MJ, Sibai B, Langer O, Thorp JM, Ramin SM, Mercer BM; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Maternal morbidity associated with multiple repeat cesarean deliveries. Obstet Gynecol. 2006 Jun;107(6):1226-32. doi: 10.1097/01.AOG.0000219750.79480.84.
Results Reference
background
PubMed Identifier
22071057
Citation
Marshall NE, Fu R, Guise JM. Impact of multiple cesarean deliveries on maternal morbidity: a systematic review. Am J Obstet Gynecol. 2011 Sep;205(3):262.e1-8. doi: 10.1016/j.ajog.2011.06.035. Epub 2011 Jun 15.
Results Reference
background
PubMed Identifier
16846571
Citation
Cahill AG, Stamilio DM, Odibo AO, Peipert JF, Ratcliffe SJ, Stevens EJ, Sammel MD, Macones GA. Is vaginal birth after cesarean (VBAC) or elective repeat cesarean safer in women with a prior vaginal delivery? Am J Obstet Gynecol. 2006 Oct;195(4):1143-7. doi: 10.1016/j.ajog.2006.06.045. Epub 2006 Jul 17.
Results Reference
background
PubMed Identifier
20979013
Citation
Gungorduk K, Yildirim G, Asicioglu O, Gungorduk OC, Sudolmus S, Ark C. Efficacy of intravenous tranexamic acid in reducing blood loss after elective cesarean section: a prospective, randomized, double-blind, placebo-controlled study. Am J Perinatol. 2011 Mar;28(3):233-40. doi: 10.1055/s-0030-1268238. Epub 2010 Oct 26.
Results Reference
background
PubMed Identifier
16108235
Citation
Magann EF, Evans S, Hutchinson M, Collins R, Lanneau G, Morrison JC. Postpartum hemorrhage after cesarean delivery: an analysis of risk factors. South Med J. 2005 Jul;98(7):681-5. doi: 10.1097/01.SMJ.0000163309.53317.B8.
Results Reference
background
Citation
Tarabrin O, Kaminskiy V, Galich S, Tkachenko R, Gulyaev A, Shcherbakov S, Gavrychenko D. (2012): Efficacy of tranexamic acid in decreasing blood loss during cesarean section. Critical Care, 16(Suppl 1): P439.
Results Reference
background
Citation
World Health Organization (2010): World health report (2010) Background Paper, No 30. Available at www.who.int/entity/healthsystems/topics/financing/healthreport/30Csectioncosts.pdf.
Results Reference
background
PubMed Identifier
24974589
Citation
Martin JA, Hamilton BE, Ventura SJ, Osterman MJ, Wilson EC, Mathews TJ. Births: final data for 2010. Natl Vital Stat Rep. 2012 Aug 28;61(1):1-72.
Results Reference
background
Citation
World Health Organization (2006): WHO Recommendations on the Prevention of Postpartum Hemorrhage. Available at www.pphprevention.org/files/who_summaryofOct.2006techconsult.pdf.
Results Reference
background
Citation
Gohel M, Patel P, Gupta A, Desai P. (2007): Efficacy of tranexamic acid in decreasing blood loss during and after cesarean section: A randomized case controlled prospective study. The Journal of Obstetrics and Gynecology of India, 57(3): 227-230.
Results Reference
background
Citation
Yehia AH, Koleib MH, Abdelazim IA, Atik A. (2014): Tranexamic acid reduces blood loss during and after cesarean section: A double blinded, randomized, controlled trial. Asian Pacific Journal of Reproduction, 3(1): 53-56.
Results Reference
background
Citation
Mitchell JL, Stecher J, Crowson J, Rich D. (2015): Uterine Cooling During Cesarean Delivery to Reduce Blood Loss and Incidence of Postpartum Hemorrhage: A Randomized Controlled Trial [79]. Obstetrics & Gynecology.
Results Reference
background

Learn more about this trial

A Novel Technique Of Uterine Cooling During Repeated Cesarean Section For Reducing Blood Loss

We'll reach out to this number within 24 hrs